{
    "Trade/Device Name(s)": [
        "InflammaDry",
        "InflammaDry External Controls"
    ],
    "Submitter Information": "Rapid Pathogen Screening, Inc.",
    "510(k) Number": "K132066",
    "Predicate Device Reference 510(k) Number(s)": [
        "K083184"
    ],
    "Regulatory Class": "Class I, exempt (InflammaDry); Class I, reserved (InflammaDry External Controls)",
    "Product Code(s)": [
        "PFQ",
        "JJX"
    ],
    "Summary Letter Date": "November 21, 2013",
    "Summary Letter Received Date": "November 20, 2013",
    "Submission Date": "November 19, 2013",
    "Regulation Number(s)": [
        "21CFR862.1540",
        "21CFR862.1660"
    ],
    "Regulation Name(s)": [
        "Osmolality test system",
        "Quality controls, chemistry"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Matrix metalloproteinase-9 (MMP-9)"
    ],
    "Specimen Type(s)": [
        "Tears"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Lateral flow immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Direct Sampling Micro-Filtration"
    ],
    "Submission Type(s)": [
        "Kit",
        "Control",
        "Quality control material",
        "Consumable"
    ],
    "Document Summary": "FDA 510(k) summary for InflammaDry and InflammaDry External Controls lateral flow immunoassay for MMP-9 detection in human tears to aid in dry eye diagnosis.",
    "Indications for Use Summary": "Visual, qualitative in vitro detection of elevated MMP-9 in human tears to aid in diagnosing dry eye, for prescription use at point-of-care; external controls are for performance verification and operator training.",
    "fda_folder": "Clinical Chemistry"
}